Ganitumab
As of the edition of 20 October 2026, Ganitumab is an antibody: stopped in 2022; acts on IGF1R.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2022
- Kind
- Antibody
- Registered trials
- 29, 11 stopped early
- Disease areas
- Cancer; Digestive system; Hormones; Urinary and reproductive; Lungs and airways; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B and 4 companies on route A because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Ganitumab.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Companies on route A for this drug
In the product4 companies are on route A because of Ganitumab.
See the 4 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| IGF1R | Insulin-like growth factor 1 receptor | P08069 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 0 | 1 | 0 |
| Phase 1 | 5 | 5 | 0 | 0 |
| Phase 2 | 20 | 8 | 1 | 11 |
| Phase 3 | 2 | 1 | 1 | 0 |
| All trials | 29 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Amgen | Lead sponsor of trials | 2005 to now |
| Immunitybio | Lead sponsor of trials | 2006 to now |
| NantBioScience | Lead sponsor of trials | 2008 to now |
| Pfizer | Lead sponsor of trials | 2012 to now |
| Novartis | Lead sponsor of trials | 2012 to now |